CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
CervoMed's lead asset neflamapimod received an Innovation Passport designation under the UK's Innovative Licensing and Access Pathway for the treatment of Dementia with Lewy Bodies. The designation, granted by UK regulators including the MHRA and NHS, recognizes the drug's potential to address a condition of high unmet need and provides a platform to accelerate development and patient access.
Key figures
- Phase 2a patients
- 91
- Phase 2b patients
- 159
- Total phase 1 2 participants
- 800
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.